The third analysis of the bicalutamide Early Prostate Cancer programme.
Iversen
Peter
P
Department of Urology, Rigshospitalet, Copenhagen, Denmark. PETERRH01943IVERSEN@rh.dk
D000726:Androgen Antagonists / Q000627:therapeutic use*; D000813:Anilides / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003627:Data Interpretation, Statistical; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D009570:Nitriles; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D014105:Tosyl Compounds
D000726:Androgen Antagonists; D000813:Anilides; D000970:Antineoplastic Agents; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide